@article{9d0e37b7300c4362b76bcaa04398e826,
title = "TAM Receptors Are Not Required for Zika Virus Infection in Mice",
abstract = "Tyro3, Axl, and Mertk (TAM) receptors are candidate entry receptors for infection with the Zika virus (ZIKV), an emerging flavivirus of global public health concern. To investigate the requirement of TAM receptors for ZIKV infection, we used several routes of viral inoculation and compared viral replication in wild-type versus Axl−/−, Mertk−/−, Axl−/−Mertk−/−, and Axl−/−Tyro3−/− mice in various organs. Pregnant and non-pregnant mice treated with interferon-α-receptor (IFNAR)-blocking (MAR1-5A3) antibody and infected subcutaneously with ZIKV showed no reliance on TAMs for infection. In the absence of IFNAR-blocking antibody, adult female mice challenged intravaginally with ZIKV showed no difference in mucosal viral titers. Similarly, in young mice that were infected with ZIKV intracranially or intraperitoneally, ZIKV replication occurred in the absence of TAM receptors, and no differences in cell tropism were observed. These findings indicate that, in mice, TAM receptors are not required for ZIKV entry and infection.",
keywords = "CNS, congenital infection, flavivirus, neurotropic virus, pregnancy, viral entry",
author = "Hastings, {Andrew K.} and Yockey, {Laura J.} and Jagger, {Brett W.} and Jesse Hwang and Ryuta Uraki and Gaitsch, {Hallie F.} and Parnell, {Lindsay A.} and Bin Cao and Mysorekar, {Indira U.} and Rothlin, {Carla V.} and Erol Fikrig and Diamond, {Michael S.} and Akiko Iwasaki",
note = "Funding Information: We thank M. Mercau; E. Louis; S. Ghosh; and members of the Rothlin lab for providing protocols, reagents, mice, and helpful discussion. We thank K. Jurado, H. Dong, and M. Linehan for technical assistance; A. van den Pol for providing the ZIKV-immune rat serum, and B. Lindenbach for providing Cambodian virus stocks. This study was supported by grants from the NIH (R01AI089824 to C.V.R., R01 AI073755, R01 AI101400, R01 AI104972, and 2R01-AI101400-05 to M.S.D. and R01 AI054359 and R21 AI131284 to A.I.) and the March of Dimes PRI Investigator award 21-FY13-28 (to I.U.M.). E.F. and A.I. are investigators with the Howard Hughes Medical Institute. C.V.R. is a Howard Hughes Faculty Scholar. I.U.M. is an Investigator in Reproductive Sciences awardee from the Burroughs Wellcome Fund. L.J.Y. is supported by NIH training grant T32GM007205, J.H. is supported by NIH training grant 4T32HL007974-15, L.A.P. is supported by NIH grant 2T32GM007067-42, and B.W.J. is supported by NIH grant 2T32AI007172-36A1. M.S.D. is a consultant for Inbios, Visterra, and Takeda Pharmaceuticals; is on the scientific advisory boards of Moderna and OraGene; and is a recipient of research grants from Moderna, Sanofi, and Visterra. Publisher Copyright: {\textcopyright} 2017 The Author(s)",
year = "2017",
month = apr,
day = "18",
doi = "10.1016/j.celrep.2017.03.058",
language = "English",
volume = "19",
pages = "558--568",
journal = "Cell Reports",
issn = "2211-1247",
number = "3",
}